Table 2. Pathological features.
| A) Pathological features of malignant group | ||||
|
Characteristics
Malignant gp (n = 60( |
||||
| Tumor size (continuous) n (%) | T1 (<2 cm) 10 (16.67%) |
T2 (2–5 cm) 22 (36.66%) |
T3-4 (>5 cm) 27 (45%) |
NA 1 (1.67%) |
|
Lymph node stage n (%) |
Negative 28 (46.66%) |
Positive (1–3 nodes) 16 (26.67%) |
Positive (>3 nodes) 15 (25%) |
NA 1 (1.67%) |
| Mitosis score n (%) | 1 7 (11.67%) |
2 44 (73.33%) |
3 9 (15%) |
|
| Tubular formation score n (%) | 1 2 (3.33%) |
2 27 (45%) |
3 26 (43.34%) |
NA 5 (8.33%) |
|
Nuclear grade n (%) |
1 4 (6.67%) |
2 40 (66.67%) |
3 16 (26.67%) |
|
|
Histological grade n (%) |
1 4 (6.67%) |
2 36 (60%) |
3 16 (26.67%) |
NA 4 (6.66%) |
|
Tumor grade n (%) |
Grade 1 (low) 7 (11.67%) |
Grade 2 (intermediate) 36 (60%) |
Grade 3 (high) 17 (28.33%) |
|
|
Hormonal receptors Estrogen receptor n (%) |
Negative 9 (15%) |
Positive 51 (85%) |
||
| Progesterone receptor n (%) | Negative 10 (16.67%) |
Positive 49 (81.67%) |
NA 1 (1.66%) |
|
|
Proliferation/cell cycle regulators
Ki67 LI n (%) |
Low (immunostaining <20%) 4 (6.67%) |
High (immunostaining ≥20%) 12 (20%) |
NA 44 (73.33%) |
|
|
HER2 Family n (%) HER2 |
Negative 52 (86.67%) |
Positive 6 (10%) |
NA 2 (3.33%) |
|
| Triple-negative phenotype n (%) | No 53 (88.33%) |
Yes 7 (11.67%) |
||
|
Nottingham prognostic index (NPI) n (%) |
Good prognostic group (⩽3.4) 10 (16.67%) |
Moderate group (3.41–5.4) 31 (51.66%) |
Poor group (>5.41) 13 (21.67%) |
NA 6 (10%) |
|
NPI+ for the biological classes n (%) |
Good prognostic group (⩽3.4) 30 (50%) |
Moderate group (3.41–5.4) 14 (23.33%) |
Poor group (>5.41) 1 (1.67%) |
NA 15 (25%) |
|
Chemotherapy n (%) |
Yes (after blood sampling) 38 (63.33%) |
No 22 (36.67%) |
||
| Peritumoural lymphovascular invasion | absent 41 (68.34%) |
suspicious 6 (10%) |
present 8 (13.33%) |
NA 5 (8.33%) |
|
DCIS in specimen
|
absent 28 (46. 67%) |
present 32 (53.33%) |
||
|
Microcalcification
|
absent 42 (70%) |
present 18 (30%) |
||
NA: Not available.
Tumor-node-metastasis (TNM) stage: Stage 0—Indicates carcinoma in situ. Tis, N0, M0, Stage I—Localized cancer. T1-T2, N0, M0, Stage II—Locally advanced cancer, early stages. T2-T4, N0, M0, Stage III—Locally advanced cancer, late stages. T1-T4, N1-N3, M0, Stage IV—Metastatic cancer. T1-T4, N1-N3, M1 [18]. The NPI was calculated using the following formula: NPI = histological grade (1–3) +LN stage (1–3; 1 = negative, 2 = 1–3 nodes positive, 3 = ⩾4 nodes positive) + (tumour size/cm × 0.2) [19].